VC Roundup: Cleave Raises $37m To Maintain Phase I Momentum, Plus $233.5m In Recent Financings

Cleave Biosciences leads off a recent slate of venture capital financings with $37m to fund ongoing Phase I programs for the lead drug from its protein homeostasis-focused platform.

chemist

Cleave Biosciences Inc. has raised a $37m Series B round to fund two ongoing Phase I clinical trials for its lead drug candidate CB-5083, initiate a third trial, and to continue its hunt for therapeutic candidates that target proteins responsible for the survival of cancer cells.

Burlingame, California-based Cleave has raised $91m in venture capital during the past five years to discover and develop drugs that...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip